Comparing the impact of beta-blockers and prostaglandin analogues on ocular surface change in glaucoma patients

The connection between glaucoma and ocular surface disease (OSD) is determined more distinct due to increasing research of these chronic and progressive diseases. The purpose of research – an assessment of an impact of beta-blockers and prostaglandin analogues on ocular surface in glaucoma patients. Data and methods. 25 patients (25 eyes) with primary open-angle glaucoma (POAG) were examined: group I – 10 patients (10 eyes) receiving antihypertensive therapy with beta-blocker timolol maleate (monotherapy); group II – 15 patients (15 eyes) receiving prostaglandin analogues (monotherapy); control group – 15 patients (15 eyes) without POAG not receiving eye drops). Results. Total tear production (Schirmer test), the stability of the tear film (Norn test), the degree of conjunctiva and cornea staining with the Bengal pink, ocular surface disease index were similar in patients of groups I and II, while differed from the control group. Measurement of the height of the tear meniscus using optical coherence tomography showed that in patients of group I it was higher than in patients of group II, but in both cases less than in individuals of the control group. Cytological results shows us atrophy, dyskeratosis in group I; proliferation in group II and no changes in normal conjunctival epithelium in group III. Conclusion. Atrophy and dyskeratosis are shown in conjunctival epithelium by using cytological method. These changes lead to abnormality of functioning of conjunctival epithelium. Proliferation may cause an increased blood supply and therefore a hyperemia of conjunctiva. Considering the changes of conjunctival epithelium PA therapy is preferable.

glaucoma and ocular surface changes, beta-blockers, prostaglandin analogues, tear meniscus by OCT, cytology, conjunctival epithelium, atrophy, proliferation

1. Abysheva L.D., Avdeev R.V., Alexandrov A.S., Arapiev M.U., Bakunina N.A., Baranova N.A., Basinskii A.S., Brezhnev A.Yu., Gazizova I.R., Galimova A.B., Gapon’ko O.V., Gar’kavenko V.V., Getmanova A.M., Gorodnichii V.V., Gusarevich A.A., Dorofeev D.A., Zhavoronkov S.A., Zavadskii P.Ch., Zakharova M.A., Zakhidov A.B., Zvereva O.G., Isakov I.N., Karimov U.R., Kondrakova I.V., Kuroedov A.V., Lanin S.N., Lovpache Dzh.N., Loskutov I.A., Molchanova E.V., Nagornova Z.M., Onufriichuk O.N., Petrov S.Yu., Rozhko Yu.I., Seleznev A.V., Tashtitova L.B., Khokhlova A.S., Shaposhnikova I.V., Shakhalova A.P. Influence of local hypotensive glaucoma therapy on the development and progression of dry eye syndrome. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2017; (2): 74–82. [In Russian]. doi: 10.21689/2311-7729-2017-17-2-74-82

2. Erichev V.P., Gankovskaya L.V., Koval’chuk L.V., Gankovskaya O.A., Dugina A.E. Interleukin-17 and it’s possible role in reparative processes in glaucoma. Glaukoma = Glaucoma. 2009; (1): 23–26. [In Russian].

3. Kurysheva N.I., Vinetskaya M.I., Erichev V.P., Artamonov V.P., Uspenskaya A.P. Permeability of bloodaqueous barrier in primary open-angle glaucoma. Vestnik oftal’mologii = The Russian Annals of Ophthalmology. 1998; 1: 10–13. [In Russian]

4. Arici M.K., Arici D.S., Topalkara A., Güler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin. Exp. Ophthalmol. 2000; 28 (2): 113–117. doi: 10.1046/j.1442-9071.2000.00237.x

5. Aritürk N., Öge İ., Baris S., Erkan D., Süllü Y., Koc F. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int. Ophthalmol. 1996; 20: 57–62. doi 10.1007/BF00212947

6. Brandt J.D., Wittpen J.R., Katz L.J., Steinmann W.N., Spaeth G.L. Conjunctival impression cytology in patients with glaucoma using long term topical medication. Am. J. Ophthalmol. 1991; 112: 297–301. doi 10.1016/s0002-9394(14)76730-3

7. Baudouin C., Garcher C., Haouat N., Bron A., Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101: 454–460. doi: 10.1016/s0161-6420(94)31322-4

8. Becquet F., Goldschild M., Moldovan M.S., Ettaiche M., Gastaud P., Baudouin C. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr. Eye Res. 1998; 17: 419–425. doi: 10.1080/02713689808951223

9. Broadway D.C., Grierson I., O’Brien C., H chings R.A. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch. Ophthalmol. 1994; 112: 1437–1445. doi: 10.1001/archopht.1994.01090230051020

10. Intersection of ocular surface disease and glaucoma. protecting ocular surface health in a glaucoma population. Rev. Ophthalmol. 2018; (Suppl.): 1–7. URL: https://www.reviewofophthalmology.com/CMSDocuments/2018/09/Akorn_RPi.pdf

11. Mietz H., Niesen U., Krieglstein G.K. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefe’s Arch. Clin. Exp. Ophthalmol. 1994; 232: 561–565. doi 10.1007/BF00182000

12. Sherwood M.B., Grierson I., Millar L., Hitchings R.A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989; 96: 327–335. doi: 10.1016/s0161-6420(89)32888-0

13. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 2081–2090. doi 10.1016/j.ophtha.2014.05.013

14. Williams D.E., Nguyen K.D., Shapourifar-Tehrani S., Kitada S., Lee D.A. Effects of timolol, betaxolol, and levobunolol on human Tenon’s fibroblasts in tissue culture. Invest. Ophthalmol. Vis. Sci. 1992; 33: 2233–2241.